Background: Despite the advent of highly active antiretroviral therapy, anal cancer remains a significant health problem in human immunodeficiency virus (HIV) patients. We present the clinical features and treatment outcomes of anal cancer in 60 HIV-positive patients over a 20-year period.
malignancies, the incidence of invasive anal cancer does not seem to correlate with CD4 cell count [5] , although some recent studies have found that a low CD4 cell nadir increases the risk of anal cancer [6, 7] . In addition, the risk of anal cancer is not declining with increasing usage of highly active antiretroviral therapy (HAART) [6] [7] [8] . People with a longer duration of HIV infection (>15 years) have a 12-fold higher rate of anal cancer than those with <5 years [9] . Hence, anal cancer is emerging as an important cause of morbidity and mortality among people living with HIV who have access to HAART. Although in the future screening and treatment of anal intraepithelial neoplasia and vaccination against high-risk human papillomavirus genotypes may reduce the risk of anal cancer, at present it remains a significant health issue.
For the last quarter of a century, the standard treatment of invasive anal canal cancers in the general population has been combined chemoradiotherapy (CRT) in an attempt to preserve sphincter function. This approach has increasingly been adopted for HIV-positive individuals too, although historically there has been some reluctance to treat HIV patients according to these standardised regimens because of concerns regarding the possibility of unacceptable toxicity [10] [11] [12] . Indeed, an early study from San Francisco suggested that this approach might be too toxic in patients with CD4 cell counts <200 mm 23 at the time of anal cancer diagnosis [13] . In this single institution series, we have examined not only the outcomes and short-term toxic effects of CRT but also the effect of this treatment on cellular immune parameters.
patients and methods
From a prospective database, we identified 60 HIV-seropositive patients with histologically confirmed anal cancer diagnosed between 1989 and 2010. Demographics, clinicopathological data, treatment regimes, CD4 cell counts and mortality data were prospectively collected. Performance status was documented at cancer diagnosis according to the Eastern Cooperative Oncology Group scale [14] . Tumours were staged using the TNM (tumour-node-metastases) classification of the American Joint Committee on Cancer (sixth edition). The Common Toxicity Criteria for adverse events version 4.0 (CTCAE v4.0) from the National Cancer Institute was used to retrospectively score the prospectively recorded early treatmentrelated toxicity. HAART is defined as the use of at least three antiretrovirals in accordance with published guidelines [15] .
chemoradiotherapy
All patients were treated with a two-phase radiotherapy technique. The phase I usually consisted of anterior and posterior opposed fields, which before 2002 delivered 45 Gy in 1.8 Gy daily fractions. A boost of up to 16 Gy in 10 daily fractions subsequently brought the total dose to known sites of disease to the region of 60 Gy. This was achieved by either using a smaller anterior-posterior opposed field or via a three to four field plan. After 2002, patients were treated according to the UK Anal Cancer Trial (ACT II) protocol [16] . The ACT II radiotherapy schedule delivers 30.6 Gy in 17 fractions in phase I and 19.8 Gy in 11 fractions in phase II. In both approaches, the phase I covered the primary tumour and regional lymph nodes including the inguinal nodes. Phase II confined radiotherapy delivery to the primary and any known sites of nodal involvement. Although usually treated with the same radiotherapy techniques, HIV-positive patients were excluded from the ACT II protocol because of toxicity concerns. 
statistical analysis
Survival was calculated from the day of anal cancer diagnosis until death (overall survival), relapse (disease-free survival) or the date of last followup. Survival duration curves were plotted according to the method of Kaplan and Meier [17] . The log-rank method was used to test for the significance of differences in survival distributions [18] . 
results
Since 1989, 60 patients were identified with HIV and anal cancer, 59 patients were male and 1 female. The clinicopathological details of the cohort are shown in Table 1 . Three patients were treated with best supportive care (two had metastatic disease and one had advanced HIV infection and stage 3B anal cancer in the pre-HAART era with a poor performance status). Six patients with anal verge cancers, which were completely excised, received no adjuvant therapy. One patient was treated with radiotherapy alone because of poor renal function. Fifty patients were treated with concurrent CRT. The median follow-up is 6.5 years (maximum 21 years). The overall survival 5-year survival for the entire cohort of 60 patients is 65% (95% CI 51% to 78%) and there was a significant difference in survival between patients diagnosed in the pre-and post-HAART eras (5-year overall survival 38% and 68% respectively, log-rank P = 0.034). A total of 19 patients died; 13 from anal cancer and 6 from HIV-related illnesses while in remission (two non-Hodgkin's lymphoma, one Kaposi's sarcoma, one progressive multifocal leucoencephalopathy and systemic cytomegalovirus infection, one Pneumocystis jiroveci pneumonia, one unknown cause).
chemoradiotherapy
Concurrent chemotherapy was mitomycin C and infusional 5-FU for 34 patients and mitomycin C and oral capecitabine for 16 patients. Five patients had elective defunctioning colostomy surgery before CRT to control symptoms of profuse diarrhoea (n = 3), anal fistula (n = 1) and faecal peritonitis (n = 1).
toxicity of CRT
The CTCAE v4.0 graded early toxic effects were prospectively recorded for 45 of the 50 patients who received CRT and are shown in Table 2 . Four patients had interruptions in their CRT treatment due to severe diarrhoea requiring a defunctioning colostomy (n = 1), acute tubular necrosis (n = 1), positioning difficulty (n = 1) and grade 2 thrombocytopaenia (n = 1). There are no significant differences in toxicity grades between patients who were on a ritonavir-boosted protease inhibitor regimen compared with other HAART therapies. Similarly, there are no significant differences in toxicity grades between patients treated with infusional 5-FU compared with those treated with oral capecitabine or between those with a CD4 cell count above and below 200 mm 23 at anal cancer diagnosis.
response, relapse and outcome of CRT
Response evaluation by computer tomography or magnetic resonance imaging and clinical examination 2-3 months after completing CRT has been completed for all 50 patients treated with CRT. A radiological complete response (CR) was achieved in 33 (67%), 13 (26%) a partial response (PR) and 4 (8%) patients had progressive disease. Four patients progressed through CRT and a further 10 relapsed following CRT and 11 of these 14 patients have died. The sites of relapse were locoregional only for seven patients, metastatic only for one patient and both for two patients. The relapse rate following CRT was 3 of 33 (10%) for those achieving CR and 7 of 13 (54%) for those attaining a PR (P < 0.0001). At progression or relapse, six patients underwent salvage surgery with abdominoperineal resections and one patient had a surgical resection of a localised recurrence. Six other patients were treated with best supportive care and one patient with neuroendocrine tumour received second-line chemotherapy. Following CRT, the disease-free survival at 5 years is 76% (95% CI:63% to 88%) and the overall survival at 5 years is 64% (95%CI 50% to 78%) as shown in Figure 1 . Six patients have died in remission following CRT, a median 1.5 years (range: 0.2-3.4 years) after diagnosis of anal cancer. Three patients died of AIDS-defining malignancies (two high-grade non-Hodgkin's lymphoma and one Kaposi's sarcoma) and three died of AIDS-defining opportunistic infections (one Pneumocystis jiroveci pneumonia, one progressive multifocal leucoencephalopathy and disseminated cytomegalovirus infection and one AIDS dementia complex and recurrent pneumonia).
immunological effects of CRT
The median CD4 cell count at diagnosis of anal cancer for the entire cohort was 305 mm 23 (range: 16-1252 mm 23 ) and was significantly higher in the post-HAART era than in the pre-HAART era (P = 0.02). CD4 cell counts were measured at Annals of Oncology original articles diagnosis of anal cancer and every 3 months thereafter for a year and are shown in Table 3 and Figure 2 . For patients treated with CRT, the median CD4 cell count fell by half during the first 3 months of therapy (P < 0.0001) and remained below pre-CRT levels throughout a year of follow-up. These effects on CD4 cell count were irrespective of whether patients received concurrent HAART or not. In contrast to the fall in CD4 cell count, there was no change in the HIV viral load for patients treated with CRT and concurrent HAART; at diagnosis 25 of 37 (68%) had an undetectable HIV viral load and this rose to 28 of 38 (85%) 1 year after diagnosis (P = 0.19).
discussion
This manuscript describes a sizeable single institution experience of patients with HIV-associated anal cancer, treated with a uniform approach over a period of 20 years. This has the benefit of consistent treatment regimes and a similar patient cohort. The median follow up was 6.5 years. Clinicopathological information and outcome data is presented for 60 consecutive patients including 50 who received CRT. This management strategy has increasingly been adopted for HIV-positive individuals with anal cancer, although historically there has been some reluctance because of concerns regarding the possibility of unacceptable toxicity [10] [11] [12] [13] . The clinical presentation of anal cancer in our patient group was similar to other studies [10, 12, [19] [20] [21] [22] [23] [24] [25] [26] . The majority of patients were treated with standard CRT treatment regimes equivalent to those used in the immunocompetent population. The CR rate recorded with CRT was 67%. Previous series, all of which included fewer patients and often restricted this approach to patients with good performance status and high CD4 cell counts, have reported CR rates of 50%-100% [12, 13, 20, 21, 23, [27] [28] [29] [30] [31] [32] [33] [34] [35] . The overall 5-year survival for the entire cohort of 60 patients is 65% and for the 50 patients treated with CRT is 64%. This is similar to three other recent manuscripts that quote 5-year overall survivals in HIV-positive patients: 61% [21] , 65% [31] and 67% [35] but substantially better than the only older paper that includes this data and recorded a 5-year overall survival of just 20% [19] . By comparison, the randomised United Kingdom Co-ordinating Committee on Cancer Research ACT I included 292 HIV-negative patients treated with CRT and the 5-year overall survival for these patients was 58% [36] . Of course, the patient demographics are Table 2 . CTCAE v4.0 recorded toxicity for patients treated with CRT (data available for 45 of 50 patients)
Comparison of ritonavir-boosted protease inhibitor [18] versus other HAART [8] Comparison of capecitabine [19] versus 5-fluorouracil [8] Comparison of CD4 <200 [15] versus CD4 ‡200 [20] Toxicity Grade 1 (29) 12 (27) 7 (16) original articles Annals of Oncology very different, more than half the patients enrolled in ACT I were women and the median age was >60 years [37] , compared with 98% male and a median age of 44 years in this series.
In the pre-HAART era, the treatment of HIV patients with anal cancer using standard CRT was frequently associated with severe side-effects, particularly skin toxicity [13, 19, [26] [27] [28] . The incidence of grade 3-4 skin toxicity in these five studies that included a total of 53 patients was 50%-78%. This led some authors to conclude that this approach was not advisable in patients with low CD4 cell counts [12, 13, 19, 26] . While HAART has not reduced the incidence of anal cancer [8, 25, 38] , the toxicity of CRT with HAART in more recent series, including this one, appears to have diminished somewhat [21, 29, 31, 32, 34, 35] . Indeed two series that describe 50 HIV patients between them, report that the incidence of side-effects from CRT was not significantly different from that observed in HIV-negative patients [20, 23] .
A landmark publication from San Francisco published in 1999 suggested that the toxicity of CRT correlated with pretreatment CD4 cell count [13] . While this was interpreted by some as suggesting that CRT was too toxic for patients with a CD4 cell count <200 mm 23 , the paper in fact concludes that the treatment-related morbidity is higher in these patients but that the anal cancer was ultimately controlled in 7 of 8 patients with pretreatment CD4 cell counts <200 mm 23 [13] . In this study, we show no difference in the grade of toxic effects between patients with CD4 cell counts above and below 200 mm 23 at diagnosis of anal cancer. Recent studies with most patients receiving concomitant HAART and CRT have similarly found no statistically significant correlation between toxicity and CD4 cell count [30] [31] [32] [33] 35] . We also found no difference in toxicity grades between patients treated with infusional 5-FU-based CRT and those treated with oral capecitabinebased CRT.
Significant pharmacokinetic interactions between HAART and chemotherapy are associated with increased treatmentrelated toxicity in HIV-associated non-Hodgkin's lymphoma and this effect is attributed to the inhibition of hepatic cytochrome P450 (CYP) microsomal enzymes by ritonavir in boosted protease inhibitor antiretroviral regimes [39] . In this study, ritonavir-boosted HAART use was not associated with higher grades of toxicity compared with other HAART therapies. This observation with CRT compared with the findings in lymphoma, probably relates to differences in the clearance of the cytotoxic agents used. For capecitabine and 5-FU, the major route of elimination is renal clearance, although catabolism by the polymorphic non-CYP enzyme dihydropyrimidine dehydrogenase has an important effect on toxicity. The pharmacology of mitomycin is less well established, although hepatic metabolism via several active intermediates is thought to be the major route of elimination [40] .
While reversible myelosuppression is a well-recognised sideeffect of CRT, the effects on cellular immunity are less well documented. One paper describes the effects of preoperative CRT on CD4 cell counts using a similar CRT schedule but excluding mitomycin, in advanced rectal cancer. Patients with HIV were excluded and the mean CD4 cell count fell by half from a pretreatment mean of 608 mm 23 and this decline 
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persisted for at least 4-6 weeks after completion of CRT [41] . A significant fall in CD4 cell count also occurs in patients with HIV who receive chemotherapy for lymphoma, even when co-prescribed HAART, although the CD4 count returns to pretreatment levels within 1-3 months of completion of chemotherapy [42] .
In this study, we show that CRT of HIV-associated anal cancer is associated with a fall in CD4 cell count regardless of HAART use. Importantly, this fall persists for at least 1 year after the end of CRT. There is very limited published data on the effect of CRT on CD4 cell counts. Fraunholz et al. [35] documented a fall in CD4 cell count in 20 patients on HAART and CRT from a median value of 347 mm 23 before CRT to 125 mm 23 , 3-7 weeks after CRT and 228 mm 23 1 year after CRT. The only other series describing the effects of CRT on CD4 cell count reports a fall for up to 8 months in 15 of 16 patients who had baseline and subsequent CD4 cell counts measured [31] . In the results presented here, six patients died in remission following CRT, three of tumours associated with immunodeficiency and three of opportunistic infections. This raises the possibility that the immunosuppression associated with CRT may have contributed to these deaths in remission from AIDS-defining illnesses that are associated with low CD4 cell counts, and highlights the importance of close monitoring of HIV patients following CRT, with screening for second malignancies. By comparison, a 9.1% increase in nonanal cancer deaths occurred during the first 5 years of follow-up after CRT compared with the radiotherapy-only arm in the ACT I trial and the majority of these excess deaths were from cardiovascular disease and second malignancies [36] . disclosure
